Rockwell Medical, Inc. (RMTI)
- Previous Close
1.4800 - Open
1.4800 - Bid 1.4400 x 100
- Ask 1.5000 x 100
- Day's Range
1.4500 - 1.5001 - 52 Week Range
1.1600 - 6.2400 - Volume
81,345 - Avg. Volume
220,429 - Market Cap (intraday)
42.579M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
www.rockwellmed.com237
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: RMTI
Performance Overview: RMTI
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RMTI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RMTI
Valuation Measures
Market Cap
43.46M
Enterprise Value
45.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.41
Price/Book (mrq)
2.04
Enterprise Value/Revenue
0.55
Enterprise Value/EBITDA
-9.79
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.09%
Return on Assets (ttm)
-8.44%
Return on Equity (ttm)
-47.68%
Revenue (ttm)
83.61M
Net Income Avi to Common (ttm)
-8.59M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
10.94M
Total Debt/Equity (mrq)
63.12%
Levered Free Cash Flow (ttm)
-5.52M